Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychedelics as a potential treatment for tobacco use disorder: a systematic review.

Discover mental health·2024
Same author

[Muscarinic M1 and/or M4 receptor agonists as potential novel treatments for psychoses].

Tijdschrift voor psychiatrie·2023
Same author

Cultural competence of mental health practitioners in the Netherlands.

The International journal of social psychiatry·2023
Same author

[The influence of maternal choline supplementation on fetal brain development and the risk of psychotic symptoms].

Tijdschrift voor psychiatrie·2023
Same author

Sexual dysfunction related to psychiatric disorders: a systematic review.

The journal of sexual medicine·2023
Same author

Maternal choline supplementation during pregnancy to promote mental health in offspring.

Early intervention in psychiatry·2023

Related Experiment Video

Updated: Jun 4, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

[Depot antipsychotics in the year 2011].

H Knegtering1, H Oolders, M A Ruijsink

  • 1Universitair Medisch Centrum Groningen. h.knegtering@lentis.nl

Tijdschrift Voor Psychiatrie
|February 15, 2011
PubMed
Summary

Long-acting injectable antipsychotics may help reduce psychotic relapses by improving medication adherence. Switching to these long-acting treatments requires a comprehensive plan including psychosocial support for best outcomes.

Related Experiment Videos

Last Updated: Jun 4, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Area of Science:

  • Psychiatry
  • Pharmacology

Context:

  • Poor adherence to oral antipsychotics is a significant challenge in managing psychotic disorders.
  • Lack of insight into illness contributes to relapse in patients with psychosis.

Purpose:

  • To evaluate the role of long-acting injectable (depot) antipsychotics in preventing psychotic relapse.
  • To outline strategies for transitioning patients from oral to depot antipsychotic formulations.

Summary:

  • Available depot antipsychotics in the Netherlands were compared, discussing their effects and the potential of depot formulations to mitigate adherence issues.
  • Literature review indicates a lack of evidence-based guidelines for choosing between oral and depot antipsychotics.
  • Depot antipsychotics do not eliminate adherence problems but make them apparent, necessitating further management.

Impact:

  • Individualized patient circumstances, including illness insight and personal preferences, are crucial in selecting oral versus depot antipsychotics.
  • Transitioning to depot antipsychotics to improve adherence should be integrated into a broader treatment framework incorporating psychosocial interventions.